Mann, Johannes F. E. http://orcid.org/0000-0002-3154-5332
Chang, Tara I.
Cushman, William C.
Furth, Susan L.
Ix, Joachim H.
Hou, Fan Fan
Knoll, Gregory A.
Muntner, Paul
Pecoits-Filho, Roberto
Sarnak, Mark J.
Tomson, Charles R. V.
Craig, Jonathan C.
Tunnicliffe, David J.
Howell, Martin
Tonelli, Marcello
Cheung, Michael
Earley, Amy
Cheung, Alfred K.
Article History
Accepted: 30 April 2021
First Online: 16 August 2021
Declarations
:
: Tara I. Chang, MD, MS: consultancy: Janssen; Novo Nordisk; grants/grants pending: Satellite Health Care*, National Institutes of Health, American Heart Association; workshop honoraria: Fresenius.Alfred K. Cheung, MD: consultancy: Boehringer Ingelheim; grants/grants pending: National Institutes of Health for SPRINT.William C. Cushman, MD: consultancy: Sanofi; grants/grants pending: National Institute on Aging*; National Institutes of Health*; and Eli Lilly*.Susan L. Furth, MD, PhD: grants/grants pending: National Institutes of Health*.Joachim H. Ix, MD, MAS: grants/grants pending: Baxter International*; National Institutes of Diabetes and Digestive and Kidney Diseases*; and American Heart Association*; travel expenses: American Society of Nephrology and Institute of Medicine.Fan Fan Hou, MD, PhD: consultancy: AbbVie and AstraZeneca; grants/grants pending: National Natural Science Foundation of China; Ministry of Science and Technology of China.Gregory A. Knoll, MD, MSc, FRCPC: grants/grants pending: Canadian Institutes of Health Research*.Johannes F.E. Mann, MD: consultancy: AstraZeneca; Bayer Healthcare; Boehringer Ingelheim; Fresenius Medical Care; Novo Nordisk; and Vifor Pharma; grants/grants pending: AbbVie; Boehringer Ingelheim; Canadian Institutes Health Research; Celgene; European Union; Idorsia; Novo Nordisk; Roche; Sanofi; and Sandoz; Speaker Bureaus: Amgen; AstraZeneca; Braun; Fresenius Medical Care; Gambro; Medice; Novo Nordisk; Roche.Paul Muntner, PhD MHS, FASH, FAHA: noneRoberto Pecoits-Filho, MD, PhD, FASN, FACP: consultancy: AstraZeneca; Akebia; Fresenius Medical Care; and Novo Nordisk; grants/grants pending: Fresenius Medical Care*; Speaker Bureaus: AstraZeneca and Novo Nordisk.Mark J. Sarnak, MD, MS: consultancy: Akebia*; grants/grants pending: National Institutes of Health*.Sheldon W. Tobe, MD, MScCH (HPTE): honorarium: CHEP+ a physician organization CPD not-for-profit organization that provides Canadian accredited continuing education. CHEP+ has received support in accordance with accreditation protocols from The University of Toronto, The Royal College of Physicians and Surgeons of Canada, Astra Zeneca, Bayer, Bristol Myers Squibb, Janssen, Pfizer.Charles R.V. Tomson, DM, FRCP: travel: Attendance at a London Hatter Institute meeting organized by the Lancet and University College London with arm’s- length funding from pharmaceutical companies.The other authors declare that they have no conflict of interest.* monies to institution
: This article does not contain any studies with human or animal subjects performed by any of the authors.
Free to read: This content has been made available to all.